There is expected to be a great deal of news flow from Imugene (ASX: IMU) as it looks to quickly attract the attention of a big pharma partner looking to bring effective cancer treatments to market.
The $33 million-capped IMU is currently developing immuno-oncology therapies and is moving ahead at a significant pace, having recently received notice that the Canadian Patent Office had issued a Grant Notice for this next generation cancer therapy that will protect specific cancer vaccination formulations for commercial interest.
IMU’s frontrunner drug candidate HER-Vaxx, is already in Phase 1b and Phase 2 trials and is interestingly further advanced than Regeneron’s cancer therapies before Regeneron was acquired for $1.6 billion by Roche.
IMU is looking to attract big pharma’s attention by 2020.
HER-Vaxx targets the same receptor as the two leading antibody drugs on the market, Herceptin and Perjeta, with annual sales of US$8.2 billion in a markety predicted to generate sales of US$36 billion by 2025.
IMU is looking to commercialise a treatment that has improved efficacy over existing treatments and is more cost efficient, which would give it a strong position in this market.
The information in this email should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
HER-Vaxx isn’t IMU’s only play here. It is also working with Arginine, a critical amino acid for the health of cancer fighting T-cells.
Again, IMU will be looking to replicate recent deals done in the space including a deal struck recently between $25 billion-capped Incyte and Calithera Biosciences in which $53 million was paid up front by Incyte.
As IMU is working off the same premise, could we see this $37.8 million capped company climb higher?
Our Latest Articles on Imugene
|Article||24-Oct-2019||IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy|
|Article||25-Jul-2019||IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking|
IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial: Tumour Reduction In Gastric Cancer
Dec 17, 2018